“…Some of these compounds include azoxystrobin, cyazofamid, cymoxanil, dimethomorph, fluazinam, fosetyl-A1, oligochitosn, oxathiapiprolin, and zoxmide ( Matheron and Porchas, 2000 ; Ivors et al, 2006 ; Keinath, 2007 ; Xu et al, 2007a , b ; Ji and Csinos, 2015 ). However, soon after their first use to manage the disease, insensitivity is often observed ( Kousik and Keinath, 2008 ; Cui et al, 2009 ; Sun et al, 2010 ; Bi et al, 2014 ; Miao et al, 2016 ).…”